Try a new search

Format these results:

Searched for:

person:rubena02

in-biosketch:yes

Total Results:

101


Neurofibromatosis : a handbook for patients, families, and health-care professionals

Rubenstein, Allan E; Korf, Bruce R
New York : Thieme, 2005
Extent: 253 p. ; 24cm
ISBN: 0865771545
CID: 1897

Plexiform neurofibromas in NF1: toward biologic-based therapy

Packer, R J; Gutmann, D H; Rubenstein, A; Viskochil, D; Zimmerman, R A; Vezina, G; Small, J; Korf, B
Neurofibromatosis type 1 (NF1) is one of the most common neurogenetic diseases affecting adults and children. Neurofibromas are one of the most common of the protean manifestations of NF1. Plexiform neurofibromas, which will frequently cause cosmetic abnormalities, pain, and neurologic deficits, are composed of 'neoplastic' Schwann cells accompanied by other participating cellular and noncellular components. There is increasing evidence that loss of NF1 expression in neoplastic Schwann cells is associated with elevated levels of activated RAS, supporting the notion that the NF1 gene product, neurofibromin, acts as a growth regulator by inhibiting ras growth-promoting activity. In addition, there is increasing evidence that other cooperating events, which may be under cytokine modulation, are important for neurofibroma development and growth. Treatment of plexiform neurofibromas has been empiric, with surgery being the primary option for those with progressive lesions causing a major degree of morbidity. The efficacy of alternative treatment approaches, including the use of antihistamines, maturation agents, and antiangiogenic drugs, has been questionable. More recently, biologic-based therapeutic approaches, using drugs that target the molecular genetic underpinnings of plexiform neurofibromas or cytokines believed important in tumor growth, have been initiated. Evaluation of such trials is hindered by the unpredictable natural history of plexiform neurofibromas and difficulties in determining objective response in tumors that are notoriously large and irregular in shape. Innovative neuroimaging techniques and the incorporation of quality-of-life scales may be helpful in evaluation of therapeutic interventions. The ability to design more rational therapies for NF1-associated neurofibromas is heavily predicated on an improved understanding of the molecular and cellular biology of the cells involved in neurofibroma formation and growth
PMID: 12041525
ISSN: 0028-3878
CID: 104909

Advances in neurofibromatosis 2 (NF2): a workshop report

Lim, D J; Rubenstein, A E; Evans, D G; Jacks, T; Seizinger, B G; Baser, M E; Beebe, D; Brackmann, D E; Chiocca, E A; Fehon, R G; Giovannini, M; Glazer, R; Gusella, J F; Gutmann, D H; Korf, B; Lieberman, F; Martuza, R; McClatchey, A I; Parry, D M; Pulst, S M; Ramesh, V; Ramsey, W J; Ratner, N; Rutkowski, J L; Ruttledge, M; Weinstein, D E
PMID: 10992163
ISSN: 0167-7063
CID: 90821

Neurofibromatosis 2, radiosurgery and malignant nervous system tumours [Letter]

Baser, M E; Evans, D G; Jackler, R K; Sujansky, E; Rubenstein, A
PMCID:2374414
PMID: 10732777
ISSN: 0007-0920
CID: 138468

Neurofibromatose : handboek voor patieenten, familieleden en professionele begeleiders = Neurofibomatosis : a handbook for patients, families, and health care professionals

Rubenstein, Allan E; Korf, Bruce R; Cornelis, Marijke
Apeldoorn : Garant, 1998
Extent: 296 p. ; 25cm
ISBN: 9053505954
CID: 1898

Neurocutaneous syndromes

Chapter by: Rubenstein AE; Lieberman F
in: Prognosis in neurology by Gilchrist JM [Eds]
Boston : Butterworth-Heinemann, 1998
pp. ?-?
ISBN: 0750698888
CID: 5157

Malignant nervous system tumors in neurofibromatosis 2 [Meeting Abstract]

Baser, ME; MacCollin, MM; Evans, DGR; Allen, J; Jackler, RK; Sujansky, E; Rubenstein, AE; Louis, DN
ISI:000071446000320
ISSN: 0002-9297
CID: 102362

The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2

Gutmann, D H; Aylsworth, A; Carey, J C; Korf, B; Marks, J; Pyeritz, R E; Rubenstein, A; Viskochil, D
OBJECTIVE: Neurofibromatosis 1 and neurofibromatosis 2 are autosomal dominant genetic disorders in which affected individuals develop both benign and malignant tumors at an increased frequency. Since the original National Institutes of Health Consensus Development Conference in 1987, there has been significant progress toward a more complete understanding of the molecular bases for neurofibromatosis 1 and neurofibromatosis 2. Our objective was to determine the diagnostic criteria for neurofibromatosis 1 and neurofibromatosis 2, recommendations for the care of patients and their families at diagnosis and during routine follow-up, and the role of DNA diagnostic testing in the evaluation of these disorders. DATA SOURCES: Published reports from 1966 through 1996 obtained by MEDLINE search and studies presented at national and international meetings. STUDY SELECTION: All studies were reviewed and analyzed by consensus from multiple authors. DATA EXTRACTION: Peer-reviewed published data were critically evaluated by independent extraction by multiple authors. DATA SYNTHESIS: The main results of the review were qualitative and were reviewed by neurofibromatosis clinical directors worldwide through an Internet Web site. CONCLUSIONS: On the basis of the information presented in this review, we propose a comprehensive approach to the diagnosis and treatment of individuals with neurofibromatosis 1 and neurofibromatosis 2
PMID: 9207339
ISSN: 0098-7484
CID: 102136

The detection of contiguous gene deletions at the neurofibromatosis 1 locus with fluorescence in situ hybridization

Leppig, K A; Viskochil, D; Neil, S; Rubenstein, A; Johnson, V P; Zhu, X L; Brothman, A R; Stephens, K
Neurofibromatosis type 1 (NF1) is a common genetic disorder characterized primarily by the development of multiple neurofibromas and pigmentary changes. The recent identification of contiguous gene deletions in NF1, a previously unrecognized molecular basis for this disorder, raises important questions regarding deletion frequency in the patient population and the role that contiguous genes may play in the physical manifestations of NF1 patients. To facilitate the identification of patients with large NF1 deletions, we have isolated clones carrying large genomic segments from the NF1 locus and tested their efficacy as probes for fluorescence in situ hybridization (FISH). Clone P1-9 spans approximately 65 kb of the NF1 gene, including exons 2-11, and clone P1-12 carries approximately 55 kb of NF1 intron 27B. FISH studies performed with P1-9, P1-12, and a set of overlapping 1F10 cosmid clones mapping telomeric to the NF1 locus identified large deletions in two new neurofibromatosis type 1 patients who, like previously characterized deletion patients, had mildly dysmorphic facial features and large numbers of cutaneous neurofibromas
PMID: 8565646
ISSN: 0301-0171
CID: 102135

Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients [Case Report]

Kayes, L M; Burke, W; Riccardi, V M; Bennett, R; Ehrlich, P; Rubenstein, A; Stephens, K
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterized by marked variation in clinical severity. To investigate the contribution to variability by genes either contiguous to or contained within the NF1 gene, we screened six NF1 patients with mild facial dysmorphology, mental retardation, and/or learning disabilities, for DNA rearrangement of the NF1 region. Five of the six patients had NF1 gene deletions on the basis of quantitative densitometry, locus hemizygosity, and analysis of somatic cell hybrid lines. Analyses of hybrid lines carrying each of the patient's chromosomes 17, with 15 regional DNA markers, demonstrated that each of the five patients carried a deletion > 700 kb in size. Minimally, each of the deletions involved the entire 350-kb NF1 gene; the three genes--EVI2A, EVI2B, and OMG--that are contained within an NF1 intron; and considerable flanking DNA. For four of the patients, the deletions mapped to the same interval; the deletion in the fifth patient was larger, extending farther in both directions. The remaining NF1 allele presumably produced functional neurofibromin; no gene rearrangements were detected, and RNA-PCR demonstrated that it was transcribed. These data provide compelling evidence that the NF1 disorder results from haploid insufficiency of neurofibromin. Of the three documented de novo deletion cases, two involved the paternal NF1 allele and one the maternal allele. The parental origin of the single remaining expressed NF1 allele had no dramatic effect on patient phenotype. The deletion patients exhibited a variable number of physical anomalies that were not correlated with the extent of their deletion. All five patients with deletions were remarkable for exhibiting a large number of neurofibromas for their age, suggesting that deletion of an unknown gene in the NF1 region may affect tumor initiation or development
PMCID:1918114
PMID: 8116612
ISSN: 0002-9297
CID: 102134